Disposition of 96778 shares by Raju Mohan of Ventyx Biosciences at 0.2 subject to Rule 16b-3
| VTYX Stock | USD 2.02 0.08 3.81% |
Slightly above 62% of Ventyx Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Ventyx Biosciences stock suggests that many investors are alarmed at this time. Ventyx Biosciences' investing sentiment can be driven by a variety of factors including economic data, Ventyx Biosciences' earnings reports, geopolitical events, and overall market trends.
Ventyx |
Filed transaction by Ventyx Biosciences Director, Officer: Ceo And President. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Ventyx Biosciences Fundamental Analysis
We analyze Ventyx Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ventyx Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ventyx Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Ventyx Biosciences is currently under evaluation in target price category among its peers.
Ventyx Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ventyx Biosciences stock to make a market-neutral strategy. Peer analysis of Ventyx Biosciences could also be used in its relative valuation, which is a method of valuing Ventyx Biosciences by comparing valuation metrics with similar companies.
Peers
Ventyx Biosciences Related Equities
| TAK | Takeda Pharmaceutical | 0.15 | ||||
| CTLT | Catalent | 0.17 | ||||
| ITCI | Intracellular | 0.31 | ||||
| HLN | Haleon Plc | 0.54 | ||||
| NBIX | Neurocrine Biosciences | 1.18 | ||||
| ALVO | Alvotech | 1.89 | ||||
| BHC | Bausch Health | 3.83 | ||||
| EBS | Emergent Biosolutions | 8.45 |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.